| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 19.9% | Goldman Sachs | → $5 | Initiates Coverage On | → Neutral |
| 08/23/2023 | 235.73% | HC Wainwright & Co. | $5 → $14 | Upgrades | Neutral → Buy |
| 08/22/2023 | 283.69% | Oppenheimer | → $16 | Reiterates | Outperform → Outperform |
| 08/22/2023 | 163.79% | Stifel | → $11 | Upgrades | Hold → Buy |
| 08/04/2023 | 19.9% | HC Wainwright & Co. | → $5 | Reiterates | Neutral → Neutral |
| 05/16/2023 | 283.69% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 05/16/2023 | 19.9% | HC Wainwright & Co. | $6 → $5 | Maintains | Neutral |
| 05/05/2023 | -28.06% | Goldman Sachs | $9 → $3 | Maintains | Neutral |
| 05/04/2023 | -28.06% | Goldman Sachs | $9 → $3 | Downgrades | Buy → Neutral |
| 03/13/2023 | 115.83% | Goldman Sachs | $17 → $9 | Maintains | Buy |
| 03/10/2023 | 67.87% | Morgan Stanley | $8 → $7 | Maintains | Equal-Weight |
| 03/10/2023 | 43.88% | HC Wainwright & Co. | $20 → $6 | Downgrades | Buy → Neutral |
| 03/10/2023 | 91.85% | Credit Suisse | $11 → $8 | Downgrades | Outperform → Neutral |
| 02/28/2023 | 379.62% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/28/2023 | 91.85% | Morgan Stanley | $27 → $8 | Downgrades | Overweight → Equal-Weight |
| 02/27/2023 | 379.62% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/27/2023 | 379.62% | Oppenheimer | $26 → $20 | Maintains | Outperform |
| 02/27/2023 | 163.79% | Credit Suisse | $19 → $11 | Maintains | Outperform |
| 01/24/2023 | 547.48% | Morgan Stanley | $26 → $27 | Maintains | Overweight |
| 01/23/2023 | 403.6% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 01/19/2023 | 307.67% | Goldman Sachs | $11 → $17 | Maintains | Buy |
| 11/15/2022 | 163.79% | Goldman Sachs | → $11 | Initiates Coverage On | → Buy |
| 11/14/2022 | 523.5% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 11/09/2022 | 355.64% | Credit Suisse | $22 → $19 | Maintains | Outperform |
| 06/13/2022 | 379.62% | HC Wainwright & Co. | $40 → $20 | Maintains | Buy |
| 05/17/2022 | 499.52% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
| 04/12/2022 | 523.5% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 03/25/2022 | 739.33% | Credit Suisse | $30 → $35 | Maintains | Outperform |
| 03/08/2022 | 691.37% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 08/17/2021 | 859.23% | HC Wainwright & Co. | $20 → $40 | Maintains | Buy |
| 08/13/2021 | 787.29% | SVB Leerink | $23 → $37 | Maintains | Outperform |
| 08/11/2021 | 619.42% | Credit Suisse | $20 → $30 | Maintains | Outperform |
| 08/11/2021 | 715.35% | Morgan Stanley | → $34 | Upgrades | Equal-Weight → Overweight |
| 03/22/2021 | 523.5% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 03/08/2021 | 187.77% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
| 03/02/2021 | 331.65% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 11/10/2020 | 451.56% | SVB Leerink | $25 → $23 | Maintains | Outperform |
| 10/16/2020 | 427.58% | Piper Sandler | → $22 | Initiates Coverage On | → Overweight |
| 08/12/2020 | 163.79% | B of A Securities | → $11 | Downgrades | Neutral → Underperform |
| 08/12/2020 | 379.62% | HC Wainwright & Co. | $28 → $20 | Maintains | Buy |
| 08/12/2020 | 163.79% | Morgan Stanley | $29 → $11 | Downgrades | Overweight → Equal-Weight |
| 06/19/2020 | 451.56% | B of A Securities | $19 → $23 | Downgrades | Buy → Neutral |
| 06/17/2020 | 547.48% | BTIG | → $27 | Initiates Coverage On | → Buy |
| 03/06/2020 | 571.46% | HC Wainwright & Co. | $21 → $28 | Reiterates | → Buy |
| 01/23/2020 | 427.58% | B of A Securities | $19 → $22 | Maintains | Buy |
| 10/03/2019 | 403.6% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 08/12/2019 | 595.44% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 08/12/2019 | 355.64% | B of A Securities | → $19 | Initiates Coverage On | → Buy |
What is the target price for Fulcrum Therapeutics (FULC)?
The latest price target for Fulcrum Therapeutics (NASDAQ: FULC) was reported by Goldman Sachs on September 25, 2023. The analyst firm set a price target for $5.00 expecting FULC to rise to within 12 months (a possible 19.90% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fulcrum Therapeutics (FULC)?
The latest analyst rating for Fulcrum Therapeutics (NASDAQ: FULC) was provided by Goldman Sachs, and Fulcrum Therapeutics initiated their neutral rating.
When is the next analyst rating going to be posted or updated for Fulcrum Therapeutics (FULC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
Is the Analyst Rating Fulcrum Therapeutics (FULC) correct?
While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a initiated with a price target of $0.00 to $5.00. The current price Fulcrum Therapeutics (FULC) is trading at is $4.17, which is within the analyst's predicted range.